MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Search

TG Therapeutics Inc

Fechado

SetorSaúde

28.5 -6.5

Visão Geral

Variação de preço das ações

24h

Atual

Mín

28.18

Máximo

28.87

Indicadores-chave

By Trading Economics

Rendimento

363M

391M

Vendas

21M

162M

P/E

Médio do Setor

10.794

87.826

Margem de lucro

241.727

Funcionários

374

EBITDA

-4.9M

33M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+42.62% upside

Dividendos

By Dow Jones

Próximos Ganhos

2 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-599M

4.7B

Abertura anterior

35

Fecho anterior

28.5

Sentimento de Notícias

By Acuity

29%

71%

66 / 370 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

TG Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jan. de 2026, 00:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Edwards Lifesciences Drops Merger With JenaValve

10 de jan. de 2026, 12:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Copper Is the Prize in Mining Megadeals -- WSJ

10 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

10 de jan. de 2026, 09:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

10 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

10 de jan. de 2026, 09:00 UTC

Ganhos

Big Banks Expected to Post Higher Profits as Shares Surge -- Barrons.com

9 de jan. de 2026, 22:18 UTC

Conversa de Mercado

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

9 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

9 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 de jan. de 2026, 21:43 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 de jan. de 2026, 20:39 UTC

Conversa de Mercado

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 de jan. de 2026, 20:38 UTC

Conversa de Mercado

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 de jan. de 2026, 20:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 de jan. de 2026, 20:30 UTC

Conversa de Mercado

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 de jan. de 2026, 20:15 UTC

Conversa de Mercado

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 de jan. de 2026, 20:07 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

9 de jan. de 2026, 20:07 UTC

Conversa de Mercado

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 de jan. de 2026, 19:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 de jan. de 2026, 19:42 UTC

Conversa de Mercado

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 de jan. de 2026, 19:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Wolters Kluwer Acquires StandardFusion >WTKWY

9 de jan. de 2026, 19:31 UTC

Ganhos

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 de jan. de 2026, 19:28 UTC

Ganhos

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 de jan. de 2026, 18:30 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 de jan. de 2026, 18:23 UTC

Conversa de Mercado

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 de jan. de 2026, 17:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

9 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jan. de 2026, 17:19 UTC

Conversa de Mercado

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 de jan. de 2026, 17:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

TG Therapeutics Inc Previsão

Preço-alvo

By TipRanks

42.62% parte superior

Previsão para 12 meses

Média 43.5 USD  42.62%

Máximo 60 USD

Mínimo 15 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para TG Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

3

Comprar

0

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 34.86Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

66 / 370 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat